STADA and Alvotech’s win first EU-approval for Stelara biosimilar
STADA and Alvotech’s Uzpruvo gained an EU marketing authorisation, allowing it to be sold in the European Economic Area in 2024.
Explore our marketing solutions
Genomics has been identified as the top emerging pharmaceutical industry trend for 2024, with its growth attributed to the increasing prevalence of chronic diseases, plummeting DNA sequencing costs, and increasing funding for genomics. Despite an optimistic outlook for 2024, the industry growth is predicted to be below 2022 levels primarily due to geopolitical conflicts, inflation, and drug pricing pressures.
